The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

RACLOPRIDE     3,5-dichloro-N-[[(2S)-1- ethylpyrrolidin-2...

Synonyms: Racloprida, Raclopridum, Meglitinides, Tocris-1810, AC1MHWAC, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of RACLOPRIDE


Psychiatry related information on RACLOPRIDE


High impact information on RACLOPRIDE


Chemical compound and disease context of RACLOPRIDE


Biological context of RACLOPRIDE


Anatomical context of RACLOPRIDE


Associations of RACLOPRIDE with other chemical compounds


Gene context of RACLOPRIDE

  • There was no difference in phosphorylated TH levels or TH catalytic activity between wild-type and alpha-synuclein knockout mice under basal conditions or following raclopride-induced acceleration of NSDA activity [32].
  • Furthermore, to determine whether NMDA receptor subtype dependence of haloperidol-induced c-Fos expression is unique to the binding profile of haloperidol or whether it is a property of D2 receptor antagonism, the selective D2/D3 dopamine receptor antagonist, raclopride, was also used [33].
  • The effect of neurotensin was abolished by tetrodotoxin (TTX) or MK801 plus CNQX, but not by SCH23390 or raclopride [34].
  • DA-D2 and glutamate receptors of NMDA subtypes also participate, albeit to a lesser extent, to THC-induced ERK activation in the striatum, as shown after injection of selective antagonists (raclopride and MK801, respectively) [35].
  • We used dopamine transporter (DAT) (-/-) mice to examine the behavioral consequences of a chronically hyperdopaminergic state, challenging them with the preferential dopamine D2 receptor antagonist raclopride and D1 receptor antagonist SCH23390 [36].

Analytical, diagnostic and therapeutic context of RACLOPRIDE

  • Local perfusion of the D(2-3) receptor antagonist raclopride produced an increase in the extracellular levels of dopamine, which was partially, but significantly, counteracted by coperfusion with dihydro-beta-erythroidine [37].
  • In contrast, the selective D2 receptor antagonist raclopride caused a greater activation of the subcortical than cortical DA projections, as assessed by microdialysis experiments in vivo from our laboratory [38].
  • Raclopride (0.25 and 0.5 mg/kg SC) and SCH23390 (0.01 and 0.02 mg/kg SC) blocked the amphetamine-induced hyperlocomotion in the lesioned and control groups [39].
  • In this exploratory, double-blind study, the relationship between plasma prolactin concentration and central D2 receptor occupancy was examined in 13 schizophrenic patients treated with the experimental antipsychotic drug raclopride (2, 6, or 12 mg daily) [40].
  • The D2 receptor blocker, raclopride, alone (1-3 mg/kg i.v.) produced changes of the activity of the EEG, mostly, short periods of slow waves and slight increases of total power [41].


  1. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Hilker, R., Klein, C., Ghaemi, M., Kis, B., Strotmann, T., Ozelius, L.J., Lenz, O., Vieregge, P., Herholz, K., Heiss, W.D., Pramstaller, P.P. Ann. Neurol. (2001) [Pubmed]
  2. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Svensson, T.H. Brain Res. Brain Res. Rev. (2000) [Pubmed]
  3. D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD. Fan, X., Hess, E.J. Neurobiol. Dis. (2007) [Pubmed]
  4. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists. Lublin, H., Gerlach, J., Mørkeberg, F. Psychopharmacology (Berl.) (1994) [Pubmed]
  5. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Xu, R., Hranilovic, D., Fetsko, L.A., Bucan, M., Wang, Y. Mol. Psychiatry (2002) [Pubmed]
  6. Dopamine and complex sensorimotor integration: further studies in a conditioned motor task in the rat. Baunez, C., Nieoullon, A., Amalric, M. Neuroscience (1995) [Pubmed]
  7. Influence of rate of administration of raclopride on akathisia and prolactin response. Movin-Osswald, G., Karlsson, P., Hammarlund-Udenaes, M., Farde, L. Psychopharmacology (Berl.) (1994) [Pubmed]
  8. Effects of D2 dopamine receptor blockade with raclopride on intracranial self-stimulation and food-reinforced operant behaviour. Nakajima, S., Baker, J.D. Psychopharmacology (Berl.) (1989) [Pubmed]
  9. Differential effects of dopamine D-1 and D-2 receptor antagonist antipsychotics on sleep-wake patterns in the rat. Ongini, E., Bonizzoni, E., Ferri, N., Milani, S., Trampus, M. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  10. Evidence for striatal dopamine release during a video game. Koepp, M.J., Gunn, R.N., Lawrence, A.D., Cunningham, V.J., Dagher, A., Jones, T., Brooks, D.J., Bench, C.J., Grasby, P.M. Nature (1998) [Pubmed]
  11. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Volkow, N.D., Wang, G.J., Begleiter, H., Porjesz, B., Fowler, J.S., Telang, F., Wong, C., Ma, Y., Logan, J., Goldstein, R., Alexoff, D., Thanos, P.K. Arch. Gen. Psychiatry (2006) [Pubmed]
  12. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Nyberg, S., Farde, L., Halldin, C. Arch. Gen. Psychiatry (1997) [Pubmed]
  13. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Farde, L., Wiesel, F.A., Halldin, C., Sedvall, G. Arch. Gen. Psychiatry (1988) [Pubmed]
  14. Evidence for D2 receptor mediation of amphetamine-induced normalization of locomotion and dopamine transporter function in hypoinsulinemic rats. Sevak, R.J., Owens, W.A., Koek, W., Galli, A., Daws, L.C., France, C.P. J. Neurochem. (2007) [Pubmed]
  15. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Linnér, L., Wiker, C., Wadenberg, M.L., Schalling, M., Svensson, T.H. Neuropsychopharmacology (2002) [Pubmed]
  16. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets. Löschmann, P.A., Smith, L.A., Lange, K.W., Jaehnig, P., Jenner, P., Marsden, C.D. Psychopharmacology (Berl.) (1991) [Pubmed]
  17. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Hoffman, D.C., Donovan, H. Psychopharmacology (Berl.) (1995) [Pubmed]
  18. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. Nishi, A., Snyder, G.L., Greengard, P. J. Neurosci. (1997) [Pubmed]
  19. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. Dresel, S.H., Kung, M.P., Huang, X.F., Plössl, K., Hou, C., Meegalla, S.K., Patselas, G., Mu, M., Saffer, J.R., Kung, H.F. J. Nucl. Med. (1999) [Pubmed]
  20. Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers. Movin-Osswald, G., Nordström, A.L., Hammarlund-Udenaes, M., Wahlén, A., Farde, L. Clinical pharmacokinetics. (1992) [Pubmed]
  21. Effect of clozapine upon schedule-induced polydipsia (SIP) resembles neither the actions of dopamine D1 nor D2 blockade. Didriksen, M., Olsen, G.M., Christensen, A.V. Psychopharmacology (Berl.) (1993) [Pubmed]
  22. Prolonged central effects of quinpirole on cardiovascular regulation. van den Buuse, M., Morton, S.J., Cornish, J.L., Head, G.A. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  23. Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study. Hersi, A.I., Richard, J.W., Gaudreau, P., Quirion, R. J. Neurosci. (1995) [Pubmed]
  24. D-Amphetamine stimulates D(2) dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats. Bhattacharjee, A.K., Chang, L., White, L., Bazinet, R.P., Rapoport, S.I. J. Cereb. Blood Flow Metab. (2006) [Pubmed]
  25. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Eltayb, A., Wadenberg, M.L., Svensson, T.H. Biol. Psychiatry (2005) [Pubmed]
  26. Bradykinesia in early Huntington's disease. Sánchez-Pernaute, R., Künig, G., del Barrio Alba, A., de Yébenes, J.G., Vontobel, P., Leenders, K.L. Neurology (2000) [Pubmed]
  27. Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions. Grebb, J.A., Girault, J.A., Ehrlich, M., Greengard, P. J. Neurochem. (1990) [Pubmed]
  28. Dopaminergic mechanism of imipramine action in an animal model of depression. Muscat, R., Sampson, D., Willner, P. Biol. Psychiatry (1990) [Pubmed]
  29. Involvement of dopamine D1 and D2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. Angulo, J.A. J. Neurochem. (1992) [Pubmed]
  30. Comparison of the effects of remoxipride and raclopride on nigrostriatal and mesolimbic dopaminergic neuronal activity and on the secretion of prolactin and alpha-melanocyte-stimulating hormone. Eaton, M.J., Tian, Y., Lookingland, K.J., Moore, K.E. Neuropsychopharmacology (1992) [Pubmed]
  31. Serotonin and pain: evidence that activation of 5-HT1A receptors does not elicit antinociception against noxious thermal, mechanical and chemical stimuli in mice. Millan, M.J. Pain (1994) [Pubmed]
  32. Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein. Drolet, R.E., Behrouz, B., Lookingland, K.J., Goudreau, J.L. J. Neurochem. (2006) [Pubmed]
  33. Role of NR2B-containing N-methyl-D-aspartate receptors in haloperidol-induced c-Fos expression in the striatum and nucleus accumbens. Lee, J., Rajakumar, N. Neuroscience (2003) [Pubmed]
  34. Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling. Matsuyama, S., Fukui, R., Higashi, H., Nishi, A. Eur. J. Neurosci. (2003) [Pubmed]
  35. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Valjent, E., Pagès, C., Rogard, M., Besson, M.J., Maldonado, R., Caboche, J. Eur. J. Neurosci. (2001) [Pubmed]
  36. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. Ralph, R.J., Paulus, M.P., Fumagalli, F., Caron, M.G., Geyer, M.A. J. Neurosci. (2001) [Pubmed]
  37. Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Quarta, D., Ciruela, F., Patkar, K., Borycz, J., Solinas, M., Lluis, C., Franco, R., Wise, R.A., Goldberg, S.R., Hope, B.T., Woods, A.S., Ferr??, S. Neuropsychopharmacology (2007) [Pubmed]
  38. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]. Svensson, T.H., Mathé, J.M., Andersson, J.L., Nomikos, G.G., Hildebrand, B.E., Marcus, M. Journal of clinical psychopharmacology. (1995) [Pubmed]
  39. Enhancement of postsynaptic sensitivity to dopaminergic agonists induced by neonatal hippocampal lesions. Wan, R.Q., Corbett, R. Neuropsychopharmacology (1997) [Pubmed]
  40. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. Nordström, A.L., Farde, L. Journal of clinical psychopharmacology. (1998) [Pubmed]
  41. Synchronization of the EEG and sedation induced by neuroleptics depend upon blockade of both D1 and D2 dopamine receptors. Bo, P., Ongini, E., Giorgetti, A., Savoldi, F. Neuropharmacology (1988) [Pubmed]
WikiGenes - Universities